Article

Neurosensory Risk After Semaglutide or Tirzepatide Is Lower Than Matched Antidiabetic and Bariatric Surgery Cohorts and Tracks Glycemic Burden

2026-07-30

Abstract excerpt

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for type 2 diabetes and obesity, but emerging evidence from randomized trials and real-world anecdotes suggest that neurosensory adverse events merit systematic investigation. We analyzed 670,422 initiators of semaglutide or tirzepatide across a large-scale federated EHR network and ascertained 14 new-onset neurosensory phenotypes over 12 m...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 948a4bf5-b5be-5bc3-ab7a-146506559bc5
DOI: 10.20944/preprints202607.2217.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Neurosensory Risk After Semaglutide or Tirzepatide Is Lower Than Matched Antidiabetic and Bariatric Surgery Cohorts and Tracks Glycemic BurdenDOI 10.20944/preprints202607.2217.v1Read

Neuro-Adverse Events Associated with GLP-1 Receptor Agonists: A Study Based on the FAERS Database and External Validation Using NHANES DatabaseSemantic proximity Read

Class-Wide Disproportionate Reporting of Impaired Gastric Emptying Across Nine Glucagon-Like Peptide-1 Receptor Agonist Products: A Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read

Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us.Semantic proximity Read

Substance-Level Disproportionate Reporting of Impaired Gastric Emptying for Five Glucagon-Like Peptide-1 Receptor Agonists: A Reproducible Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read

Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotypingSemantic proximity Read

Clinical efficacy landscaping in genetic obesity: A meta-analysis in Prader Willi syndrome (PWS)Semantic proximity Read

Oral Health Outcomes with GLP1 Receptor Agonists Compared with Other Metabolic InterventionsSemantic proximity Read

Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature reviewSemantic proximity Read

Exenatide Is Associated with Superior Gastrointestinal Motility Slowing Among GLP-1 Receptor AgonistsSemantic proximity Read

Cardiovascular Outcomes of Tirzepatide vs Semaglutide in Obesity Without Type 2 Diabetes: A Matched Cohort StudySemantic proximity Read

Pharmacogenomics of GLP-1 Receptor Agonists: Precision Medicine in the Age of Ozempic and MounjaroSemantic proximity Read